Enveric Biosciences Advances EB-003 Toward IND, Reports $1.6M Q1 Loss
Enveric Biosciences reported a Q1 net loss of $1.6 million ($1.08/share) on cash-on-hand of $4.9 million, raising $2.8 million through offerings and securing $5 million at a private placement close with up to $13.9 million potential proceeds. The company advanced its lead candidate EB-003 toward IND-enabling studies after preclinical assays demonstrated dual Gq and β-arrestin signaling at 5-HT2A receptors and a rapid reduction in conditioned fear response.
1. Q1 Financial Results
Enveric Biosciences posted a net loss of $1.6 million ($1.08 per share) for the quarter ended March 31, 2026, compared with a $2.2 million loss ($14.58 per share) in Q1 2025. The company held $4.9 million in cash at quarter end, reflecting ongoing preclinical and corporate expenses.
2. Capital Raise and Cash Position
During Q1, Enveric raised $2.8 million through registered offerings and subsequently closed a private placement with $5 million in upfront proceeds and up to $13.9 million in additional warrant-driven funding. As of May 15, the cash balance reached approximately $10.3 million, sufficient to support operations into the first quarter of fiscal 2027.
3. EB-003 Preclinical and Development Progress
Enveric’s lead candidate, EB-003, demonstrated dual Gq and β-arrestin signaling at 5-HT2A receptors in BRET assays and produced rapid reduction of conditioned fear in a validated PTSD model. IND-enabling activities are underway, positioning the company for first-in-human trials.
4. Intellectual Property and Strategic Position
The withdrawal of the Post-Grant Review petition by AbbVie underscores the strength of Enveric’s patent portfolio, which now includes expanded claims for non-hallucinogenic neuroplastogens and five newly registered Canadian trademarks. The company also extended its collaboration with TOTEC Pharma under a trademark license and option agreement.